K-V sues FDA over Makena in fight for survival | Reuters:
"FDA DILEMMA
The FDA normally issues warning letters to distributors of unapproved drugs, or may seize their products.
The FDA recently launched a drive to remove all unapproved drugs from the market due to safety issues, and encouraged companies to apply for formal clearance, but has not taken a hard line against the pre-term birth medications.
Patients and insurers preferred the pharmacy compounds, which cost $10 to $20 per injection versus the $1,500 K-V initially sought to charge for Makena after it was approved in February 2011.
K-V reportedly tried to stop pharmacies from compounding the drug by sending them letters saying they were violating the law and threatening to sue them."
'via Blog this'
The case is K-V Pharmaceutical Company v. FDA, U.S. District Court, District of Columbia, No. 12-01105.
Learn more about the case at: Complaint Filed in K-V v. FDA, case number 12-01105
Return Home: The Designated Representative and Exemptee Blog
CA Designated Representative online CBT training certification by SkillsPlus Intl Inc. - The Best. Popular. Convenient. Respected.
CA HMDR Exemptee online CBT training certification by SkillsPlus Intl Inc.
FL Designated Representative online CBT exam preparation by SkillsPlus Intl Inc.
SkillsPlus Intl Info Blog
Custom Search
